Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients

Wensi Qian, 1,* Li Wang, 2,* Pei Li, 3,* Yingwei Hu, 1 Qian Wang, 3 Ke Yi, 1 Min Wu, 1 Yu Xu, 1 Jin Song, 1 Pingping Chen, 1 Hongdi Zhang, 1 Jiexian Ma, 1, 4 Yanhui Xie 1 1Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, People’s Republic of China; 2...

Full description

Bibliographic Details
Main Authors: Qian W, Wang L, Li P, Hu Y, Wang Q, Yi K, Wu M, Xu Y, Song J, Chen P, Zhang H, Ma J, Xie Y
Format: Article
Language:English
Published: Dove Medical Press 2020-01-01
Series:Cancer Management and Research
Subjects:
multiple myeloma
arsenic trioxide
bortezomib
overall survival
treatment response
Online Access:https://www.dovepress.com/efficiency-and-tolerability-of-induction-and-consolidation-therapy-wit-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/efficiency-and-tolerability-of-induction-and-consolidation-therapy-wit-peer-reviewed-article-CMAR

Similar Items